Joe DePinto

Joe DePinto of McKesson outlines the workflow barriers slowing CGT migration to community oncology, the reimbursement reforms needed to scale access, and the pharmacist’s pivotal role in making it all work.

Joe DePinto of McKesson discusses how payers, providers, and employers diverge on CGT reimbursement—and why outcomes-based payment models may hold the key to broader patient access.

Experts emphasize the need to understand patient journeys, navigate complex value chains, and strategically match the right patients with groundbreaking therapies.

Clinicians' enthusiasm for cell and gene therapies is tempered by practical concerns.

Manufacturers can benefit by partnering with an integrated channel services provider that offers both third-party logistics and hub services.